Pharmacokinetics
Single-dose and steady-state plasma PK parameters of baxdrostat are presented in Supplementary Table Plasma Baxdrostat Concentration vs. Time on Days 1 and 10. Plasma baxdrostat concentration (ng/mL) by scheduled time point and treatment. Data are mean ± standard deviationAn exploratory analysis to assess dose proportionality demonstrated that with increasing doses of baxdrostat there was a proportional increase in both CAlthough CIN-107-M is not believed to contribute substantially to the effects of baxdrostat, its prevalence warrants characterization. On average, CIN-107-M represents 8 to 11% of the parent compound based on C